# Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

> **NCT06927960** · PHASE1 · COMPLETED · sponsor: **AnHorn Medicines Co. Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** AH-001 or placebo

## Key facts

- **NCT ID:** NCT06927960
- **Lead sponsor:** AnHorn Medicines Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-24
- **Primary completion:** 2025-07-16
- **Final completion:** 2025-07-16
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927960, "Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06927960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*